Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Effect of RNS60 on ALS Biomarkers

Trial Profile

The Effect of RNS60 on ALS Biomarkers

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RNS 60 (Primary) ; RNS 60 (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Biomarker; Pharmacodynamics
  • Acronyms RNS60
  • Most Recent Events

    • 07 Dec 2021 According to a Revalesio media release, data presented at the ALS/MND International Symposium 2021.
    • 07 Dec 2021 Results presented in a Revalesio Media Release.
    • 05 Nov 2021 Status changed from recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top